TNKPVI

TNKPVI is a biostable, potato-derived bioactive peptide (specifically a hexapeptide fragment of the potato patatin-derived decapeptide DIKTNKPVIF) being developed by Northeastern University, the University of Ottawa, and the State University of New York at Fredonia. It acts as an anti-inflammatory and antioxidant agent. TNKPVI has been shown to attenuate reactive oxygen species (ROS) production, activate the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, and inhibit the formation of neutrophil extracellular traps (NETs). It also reduces the levels of key pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α). TNKPVI is primarily being investigated for the treatment of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, as well as other NET-associated inflammatory disorders.

Other names

DIKTNKPVIF fragmentpotato-derived peptide 2261086potato-derived peptide TNKPVIThr-Asn-Lys-Pro-Val-Ile